Abstract
Complex mechanisms have evolved that control feeding and energy homeostasis in mammals. Centrally, particularly in the hypothalamus, numerous neurotransmitters have been identified that regulate appetite and energy homeostasis. On the other hand, hormones released from the gut signal states of hunger and satiety to the brain. From the large number of players involved in this interplay, peptides from the neuropeptide Y (NPY) family are unique, with the predominantly neuronally expressed NPY being one of the most strongly stimulating agents for food intake while its two other closely related family members peptide YY (PYY) and pancreatic polypeptide (PP) released from the gut induce satiety. Another major player in this circuitry is ghrelin, which is released from the stomach and is the only known hormone that signals hunger to the brain. It is doing this by stimulating hypothalamic NPY production and release, subsequently leading to increased appetite and feeding behaviour. Deregulation of these processes can lead to either the development of obesity or the other extreme, anorexia. The aim of this review is to summarize the recent literature on NPY and ghrelin and its involvement in anorexia nervosa.
Keywords: Neuropeptide Y (NPY) family, ghrelin, anorexia, energy homeostasis, osteoporosis, hypothalamus, neurotransmitters, peptide YY (PYY), pancreatic polypeptide (PP), anorexia nervosa.
Current Pharmaceutical Design
Title:The Role of NPY and Ghrelin in Anorexia Nervosa
Volume: 18 Issue: 31
Author(s): Lei Zhang, Miyuki Yagi and Herbert Herzog
Affiliation:
Keywords: Neuropeptide Y (NPY) family, ghrelin, anorexia, energy homeostasis, osteoporosis, hypothalamus, neurotransmitters, peptide YY (PYY), pancreatic polypeptide (PP), anorexia nervosa.
Abstract: Complex mechanisms have evolved that control feeding and energy homeostasis in mammals. Centrally, particularly in the hypothalamus, numerous neurotransmitters have been identified that regulate appetite and energy homeostasis. On the other hand, hormones released from the gut signal states of hunger and satiety to the brain. From the large number of players involved in this interplay, peptides from the neuropeptide Y (NPY) family are unique, with the predominantly neuronally expressed NPY being one of the most strongly stimulating agents for food intake while its two other closely related family members peptide YY (PYY) and pancreatic polypeptide (PP) released from the gut induce satiety. Another major player in this circuitry is ghrelin, which is released from the stomach and is the only known hormone that signals hunger to the brain. It is doing this by stimulating hypothalamic NPY production and release, subsequently leading to increased appetite and feeding behaviour. Deregulation of these processes can lead to either the development of obesity or the other extreme, anorexia. The aim of this review is to summarize the recent literature on NPY and ghrelin and its involvement in anorexia nervosa.
Export Options
About this article
Cite this article as:
Zhang Lei, Yagi Miyuki and Herzog Herbert, The Role of NPY and Ghrelin in Anorexia Nervosa, Current Pharmaceutical Design 2012; 18 (31) . https://dx.doi.org/10.2174/138161212803216988
DOI https://dx.doi.org/10.2174/138161212803216988 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Neurologic and Cardiovascular Complications in Pediatric Life Threatening Imipramine Poisoning
Current Drug Safety Arachidonate Cascade in the Intensive Insulin Therapy for Critically Ill Patients with Sepsis: Roles of Prostaglandins on Hyperglycemia-Impaired Immunity
Letters in Drug Design & Discovery New Antipsychotics in Treatment of Mood Instability and Cognitive Perceptual Symptoms in Borderline Personality Disorder
Current Psychopharmacology Cognitive Impairment in the Septic Brain
Current Neurovascular Research Novel Antibody Therapeutics Targeting Mesothelin In Solid Tumors
Clinical Cancer Drugs Immunotherapy of Melanoma
Current Molecular Pharmacology Prolonged Exposure to Ketamine Increases Brain Derived Neurotrophic Factor Levels in Developing Rat Brains
Current Drug Safety Is It Possible to Apply Secondary Stroke Prevention Guidelines to Very Old Populations?
Cardiovascular & Hematological Disorders-Drug Targets Scorpion Toxin Polyptides as Therapeutic Agents: An Overview
Protein & Peptide Letters Endovascular vs. Open Repair of Abdominal Aortic Aneurysms and Renal Function
Current Vascular Pharmacology Medico-Legal Evaluation of Fatal Perinatal Asphyxia
Current Pediatric Reviews Age-related Changes in Pharmacodynamics: Focus on Drugs Acting on Central Nervous and Cardiovascular Systems
Current Drug Metabolism Role of the 5-HT2C Receptor in Atypical Antipsychotics: Hero or Villain?
Current Medicinal Chemistry - Central Nervous System Agents Salusins in Hypertension and Related Cardiovascular Diseases
Current Drug Metabolism Iatrogenic Right Atrial Thrombus Complicated by Pulmonary Embolism: Management and Outcomes
Current Cardiology Reviews Pharmacology of Ivabradine and the Effect on Chronic Heart Failure
Current Topics in Medicinal Chemistry Digital Ulcers in Systemic Sclerosis – How to Manage in 2013?
Current Rheumatology Reviews New Mucoadhesive Polymeric Film for Ophthalmic Administration of Acetazolamide
Recent Patents on Drug Delivery & Formulation Troponin in Newborns and Pediatric Patients
Cardiovascular & Hematological Agents in Medicinal Chemistry Novel Immunotherapies for Hematological Malignancies
Current Molecular Pharmacology